|The following convention has been utilised for the classification of undesirable effects: very common (>1/10), common (>1/100, <1/10), uncommon (>1/1000, <1/100), rare (>1/10,000, <1/1000), very rare (1/10,000). Adverse event frequencies have been estimated from spontaneous reports from post-marketing data.
Blood & Lymphatic System Disorders
|Very Rare:||Blood count changes (leucopenia, thrombocytopenia). These are usually reversible. Agranulocytosis or pancytopenia, sometimes with marrow hypoplasia or marrow aplasia.|
Immune System Disorders
These events have been reported after a single dose.
|Rare:||Hypersensitivity reactions (urticaria, angioneurotic oedema, fever, bronchospasm, hypotension and chest pain).|
|Very Rare:||Anaphylactic shock|
These have been reported predominantly in severely ill and elderly patients.
|Very Rare:||Reversible mental confusion, depression and hallucinations.|
Nervous System Disorders
|Very Rare:||Headache (sometimes severe),dizziness and reversible involuntary movement disorders.|
There have been reports of blurred vision, which is suggestive of a change in accommodation.
|Very Rare:||Reversible blurred vision.|
|Very Rare:||As with other H2 receptor antagonists bradycardia and A-V Block.|
|Very Rare:||Acute pancreatitis. Diarrhoea.|
|Uncommon:||Abdominal pain, constipation, nausea (these symptoms mostly improved during continued treatment)|
|Rare:||Transient and reversible changes in liver function tests.|
|Very Rare||Hepatitis (hepatocellular, hepatocanalicular or mixed) with or without jaundice, these were usually reversible.|
Skin and Subcutaneous Tissue Disorders
|Very Rare:||Erythema multiforme, alopecia.|
Musculoskeletal and Connective Tissue Disorders
|Very Rare:||Musculoskeletal symptoms such as arthralgia and myalgia.|
Renal and Urinary Disorders
|Very rare:||Acute interstitial nephritis.|
|Rare:||Elevation of plasma creatinine (usually slight; normalised during continued treatment).|
Reproductive System and Breast Disorders
The safety of ranitidine has been assessed in children aged 0 to 16 years with acid-related disease and was generally well tolerated with an adverse event profile resembling that in adults. There are limited long term safety data available, in particular regarding growth and development.
|Very Rare:||Reversible impotence, breast symptoms and breast conditions (such as gynaecomastia and galactorrhoea)|